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Abstract
Background: Pegylated liposomal doxorubicin (PLD), a formulation with pharmacokinetic differences with respect
to doxorubicin (DXR), might benefit patients with advanced soft tissue sarcoma (STS) pretreated with DXR.
Patients and methods: Patients with measurable and progressive STS received PLD at 35mg/m
2 every 3 weeks. Quality
of life before and during treatment was assessed with EORTC QLQ-C30.
Results: Twenty-eight patients, 22 DXR-pretreated, were given 140 cycles (median 3, range 1–18). Activity in 27 patients
(5 GIST): one complete and one partial remission (both non-GIST and without prior DXR), 12 stabilizations and
13 progressions (response rate 7.4%, 95% CI: 0–17%). Grade 3 toxicity: palmar-plantar erythrodysesthesia (19% of
patients), stomatitis (4%) or cutaneous (4%). Neutropenia grade 3 was detected in 16% of patients. Median relative
dose intensity was 95%. Progression-free rate at 3 and 6 months was, respectively, 48 and 22%, median progression-free
survival 5.8 months and median overall survival 8.7 months. QLQ-C30 at baseline and at weeks 6–11 in 23 and 13 patients,
respectively, showed good reliability and validity. Quality of life did not seem to worsen during therapy.
Conclusions: PLD did not induce objective remissions in 22 STS patients pretreated with DXR, but progression-free
rate figures support the use of this agent in patients who have not progressed under a DXR-containing regimen.
The toxicity observed was comparable to that of other PLD schedules.
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Introduction
For advanced soft tissue sarcomas (STS) of the
adult, doxorubicin is one of the drugs which has
shown a 20–30% objective activity [1], but total
dose is limited by the risk of developing myocar-
diopathy, a side effect related to DXR peak
plasma concentrations as well as cumulative dose.
Liposomal technology has been applied to achieve a
slower DXR liberation, in an attempt to overcome
this problem. In pegylated liposomal doxorubicin
(PLD), polyethylene glycol provides an outer layer
that protects the liposome from uptake by the
reticuloendothelial system. This facilitates the dis-
tribution of liposomes to the tissues and to the tumor
bed, and DXR plasma half-life is considerably
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250-fold when compared to equivalent DXR doses,
what may influence its antitumor efficacy [2,3].
This pharmacokinetic behavior influences the
toxicity profile of PLD, so that palmar-plantar
erythrodysesthesia (PPE) or mucositis are usually
dose-limiting, hematological toxicity is less accentu-
ated, and cardiotoxicity is lower [3–5]. PLD toxicity
is schedule-dependent, and can be modified by
reducing the dose or by increasing the dose interval
[4,6,7].
In 1997 our Group planned a Phase II study
with PLD in STS patients to determine whether
this DXR formulation could provide some benefit
to patients already exposed to chemotherapy,
including DXR. Recommended doses varied from
50 to 60mg/m
2 every 4–6 weeks [6–8] and, in an
attempt to reduce toxicity, we selected a dose of
35mg/m
2 repeated every 3 weeks, which offered a
dose-intensity similar to that of previously tested
schedules. Another objective of the trial was to assess
the quality of life of patients during PLD therapy.
Patients and methods
Patients
Patients should have a histological STS diagnosis;
advanced, measurable and unresectable progressive
disease after DXR and ifosfamide; performance
status 2 (WHO); adequate bone marrow (haemo-
globin>9g/dl, granulocytes>1.5 10
9/l and
platelets 100 10
9/l), liver (serum bilirubin, AST
and ALT values<2UNL) and renal (serum
creatinine<1.5UNL) functions; left ventricular
ejection fraction (LVEF)  50%; prior cumulative
dose of doxorubicin  300mg/m
2. Patients with
NYHA class  II cardiomyopathy, or radiotherapy
over the only measurable lesion, were excluded.
Patients progressing  6 months from any DXR-
containing regimen for advanced disease, or <12
months if adjuvant, were considered resistant to
DXR. Ethics Committee of participating institutions
approved the study and informed patients signed a
consent form.
Treatment and evaluation criteria
The drug for this study was kindly provided by
Schering-Plough Espan ˜a S.A. All patients received
PLD (Caelyx, Doxil) at 35mg/m
2 over 1h, every
3 weeks.
Toxicity was evaluated according to NCI
Common Toxicity Criteria, version 1.0. Cycles were
repeated on day 21 if granulocytes>1.0 10
9/l
and any other toxicity had reached grade 1.
If granulocyte nadir was <0.5 10
9/l, the dose
was reduced by 25%. Patients with grade 1PPE,
stomatitis, esophagitis or cutaneous toxicity on day
21, who had not suffered a similar episode of grade
3–4, repeated the cycle on schedule; otherwise,
cycle was delayed until complete recovery, and the
dose reduced by 25% if a 2-week delay was
necessary. Patients were removed from study if
grade 3–4 toxicity was still present at day 35 or
if >2 dose reductions were necessary. Patients with
a confirmed LVEF<45% abandoned the study.
Patients were controlled weekly for toxicity.
LVEF was measured every 6 weeks. Only cycles
with weekly BCC were analyzed for hematological
toxicity, and patients receiving one PLD dose were
assessed for toxicity. Target lesions were evaluated
every two cycles (or 6 weeks). WHO criteria for
activity were applied [9] and patients continued
on study until disease progression or excessive
toxicity occurred. Time to progression, progres-
sion-free survival and overall survival were estimated
by actuarial methods.
Authorization to utilize the quality of life
questionnaire C30 (QLQ-C30), version 1.0 (10),
was obtained from the EORTC Quality of Life Unit.
It was to be administered to patients before
treatment and every other cycle. Scoring was
performed according to the EORTC QLQ-C30
Scoring Manual recommendations [11].
Statistics
Sample size was calculated according to a minimax-
design [12]. For P0¼10% and P1¼25% DXR
activity in first line, and  and  errors equal to 0.1,
the initial sample size was 27 patients. If two or less
responses were observed in the first 27 patients,
the study would be considered not worth expanding.
Evaluation of QLQ-C30 results were performed
as recommended [10]. The internal consistency of
QLQ-C30 was assessed by Cronbach’s  coefficient,
with values >0.70 considered acceptable [13].
Pearson’s r was calculated to check the validity
of the questionnaire, and values >0.40 indicated
substantial correlations among the different scales.
Results
Patient characteristics
From June 1998 to June 1999, 28 patients entered
this study (Table I). One of the six patients with
a retrospective GIST diagnosis died of tumor-related
complications 2 weeks after the first cycle and was
not evaluable. Another patient received only one
cycle due to rapid disease progression. In total,
140PLD cycles were delivered, (median 3, range
1–18). All patients had received one prior che-
motherapy regimen (24 for advanced disease, four
adjuvant) that in 23 had included DXR. Median
cumulative dose of doxorubicin per patient
was 200mg/m
2 (range 50–300). Eleven out of 18
128 A. Poveda et al.non-GIST patients were resistant and seven were
potentially sensitive to DXR, with all GIST patients
being resistant.
Toxicity
Maximum hematological toxicity noted was anemia
of grade 3 in 4% of patients, granulocytopenia grade
3–4 in 16% and thrombocytopenia grade 2 in 4%.
Toxicity on granulocytes was not cumulative and
nadir occurred by day 21 (median). PPE reached
grade 3 in five patients, three of whom had to
abandon the study for this toxicity (Table II). PPE
grade 3 was noted after a median of five cycles (range
3–8), with a cumulative incidence in cycles 3–8 of
1.4, 1.1, 4, 4.6, 5 and 6%, respectively. A patient
with persistent grade 2 stomatitis in spite of two dose
reductions was also removed from the study.
Cutaneous toxicity was described as a psoriasiform
eruption in one patient, and as a pruriginous
erythema in 10, only in one reaching grade 3
concomitantly with grade 3PPE. In this patient the
lesions had a lichenoid appearance and a diagnosis
of neoplastic epidermal toxicity was made upon
biopsy [14].
Asthenia of grade 3 was noted in three patients
and infection of grade 3, unrelated to therapy,
occurred in one patient. No hypersensitivy reactions
or episodes of cardiac failure were registered.
Median cumulative anthracycline (prior doxorubicin
plus PLD) was 350mg/m
2 (range 70–577). Two
out of 17 patients with serial LFEV showed a
transient decrease of 25 and 14%, respectively.
PLD was delayed a median of 7 days (range 7–14)
in 21 cycles, due to hematological (6), muco-
cutaneous toxicity (13) or other reasons (2), and
it was reduced by 25% in five patients. Cumulative
PLD was 141mg/m
2 (35–567), dose intensity
11mg/m
2/week (7–12), and relative dose intensity
of 95% (0.61–1.03) (median, range).
Response to therapy and survival
Objective activity in 27 evaluable patients included
one complete (CR) and one partial remission (PR),
12 stabilizations (NC) and 13 progressions (PD)
(response rate 7.4%; 95% CI, 0–17%). One out
of five patients with a GIST diagnosis had a <50%
reduction of liver metastases, one had disease
stabilization and three progressed. If GIST patients
are excluded, the remission rate was 9% (95% CI,
0–21%). Objective remissions were noted in two
out of five patients without prior DXR exposure after
five and 18 PLD cycles, and lasted 6 months.
In 22 patients with prior DXR treatment, 12 stabili-
zations and 10 progressions were noted. Median
duration of stable disease was 4.7 months (range
2.7–12 months). Among non-GIST patients,
11 DXR-resistant had three stabilizations and eight
progressions, with seven stabilizations noted in
seven patients with potentially DXR-sensitive disease
(Fisher exact test, P¼0.004). Progression-free
rate (PFR) at 3 and 6 months was, respectively,
48 and 22% for the whole group, 40 and 40% for
Table I. Patient characteristics.
Number 28
Male/Female 15/13
Age (median, range) 54.4 (28–74)
Performance status
01 0
11 4
24
Histological type of sarcoma
GIST 6
Leiomyosarcoma 4
Malignant fibrous histiocytoma 3
Synovial sarcoma 3
Liposarcoma 2
Neurogenic sarcoma 2
Other 8
Grade of malignancy
12
21 0
31 6
Primary site
Extremities and trunk wall 18
Gastrointestinal 5
Uterine 3
Other 2
Sites of disease
Lung 19
Primary tumor 6
Liver 6
Intra-abdominal 4
Lymph node 5
Soft-tissues 2
Prior chemotherapy
Doxorubicin ifosfamide 23
High-dose ifosfamide 3
Ifosfamide cis-platinum 2
Treatment-free interval (months)
(median, range) 4.6 (0.83–37)
Table II. Maximum grade of toxicity observed per patient.
Grade 0 1 2 3
Nausea 61 34 4 –
Vomiting 73 19 8 –
Stomatitis 42 23 31 4
Esophagitis 85 15 – –
Cardiac 92 8 – –
Cephalea 84 16 – –
Asthenia 39 31 19 11
Anorexia 58 19 15 8
Fever 73 27 – –
Infection 85 11 – 4
Pruritus 85 11 4 –
Cutaneous 62 15 19 4
PPE 34 34 12 19
Alopecia 90 5 5 –
Figures represent percentage of patients.
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those with prior DXR therapy. Median progression-
free survival was 5.8 months (95% CI: 1.4–10
months) (Figure 1), and all but two patients have
died with a median overall survival of 8.7 months
(95% CI: 2.8–15 months) (Figure 2).
Quality of life
A baseline QLQ-C30 was available from 23 patients,
with evaluations obtained from 13 patients at
weeks 6–11, and from seven patients at weeks
12–18. In Table III we present mean score values
( standard deviation) of the different scales with
the corresponding Cronbach’s  coefficients for
multi-item scales. All correlations among QLQ-
C30 scales before treatment were significant
(P<0.056); those same correlations within weeks
6–11 (n¼13) were significant, except for the pairs
global quality of life–physical (P¼0.16), fatigue–
social (P¼0.13) and nausea and vomiting–
role (P¼0.10) (data not shown). No significant
differences were noted when scores at weeks 6–11
or at week >12 were paired-compared with the
respective baseline values. Correlation of the
initial WHO performance status and the scale for
global quality of life (QLQ-C30) at baseline showed
a certain trend for lineal correlation (VCramer¼0.753
and contingency coefficient¼0.794, both with
P¼0.062).
Discussion
The activity of PLD administered at 35mg/m
2
every 3 weeks to patients with STS previously treated
with doxorubicin, measured in terms of objective
remissions, is negligible. Prior studies have been
conducted with PLD doses that varied from 50
to 60mg/m
2 repeated every 3–4 weeks. In two trials,
where most patients had received DXR, five out
of 45 STS patients responded [15, 16], and two
small studies conducted in previously untreated
patients gave negative results [17,18]. In a first-line
comparative study of the EORTC STBSG,
50 patients received PLD and 45DXR, with a
remission rate, respectively, of 10 and 9%, with no
differences detected in time to progression or
overall survival [19]. Progression-free rate has been
proposed as a parameter to evaluate the activity
of new agents in patients with advanced STS. In
this trial, progression-free rates at 3 and 6 months
were higher than the 39 and 14% encountered,
respectively, for active drugs delivered as second-
line regimens [20]. Those figures may be explained
by a potential DXR sensitivity in our patient
population, as 50% of non-GIST patients had
either not received DXR or not progressed during
a DXR-containing regimen, supporting the admin-
istration of PLD to patients who have not progressed
under DXR therapy.
Phase II trials conducted with PLD have been
usually performed at 50mg/m
2 delivered every
4 weeks, with stomatitis grade 3–4 noted in 4–9%
of patients and PPE grade 3–4 in 17–20% [19,21].
In this trial PPE appeared in 65% of patients and
stomatitis grade 2–3 was reported by 35%. Intensity
and incidence of stomatitis and PPE have been
related, respectively, to dose and cycle interval.
Grade 2–4 stomatitis occurred in 83% of patients
receiving PLD at 70mg/m
2 every 6 weeks, and
grade 2–3 PPE appeared in 73% of those treated at
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Figure 1. Progression-free survival.
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Figure 2. Overall survival.
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2 every 3 weeks, both schedules with a
dose intensity of 11.6mg/m
2 per week, equivalent to
ours [22]. Mucositis was also dose-limiting in
another trial with 70mg/m
2 PLD delivered every 6
weeks [23]. The schedule we tested did not cause
a higher PPE incidence than regimens where PLD
was delivered every 4 weeks and, in our case, the
intensity of stomatitis was lower. Grade 3–4 granu-
locytopenia (16% of patients) was higher than the
2–6% reported with PLD at 50mg/m
2 every 4 weeks
[19,21], but in our trial 93% of cycles had
weekly BCCs. No episodes of cardiac failure were
observed, and the lower cardiac toxicity of PLD
with respect to DXR has been confirmed in a recent
study [24].
Quality of life before treatment was measured
in 23 patients with the EORTC QLQ-C30 (version
1.0). To our knowledge, this questionnaire had
not been passed before to STS patients, and the
limited data obtained here point to its adequacy to
measure the quality of life of sarcoma patients
exposed to chemotherapy. In 13 patients with
assessable data, quality of life did not seem to
worsen during therapy.
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